MRI Agent Pixxoscan is an innovative contrast agent that facilitates the visualisation of abnormal structures or lesions, playing a crucial role in differentiating between healthy and pathological tissue. Developed as an alternative to the reference product Gadovist, Pixxoscan (gadobutrol) is indicated for use in individuals of all ages, including term neonates, adults, and adolescents. It is designed explicitly for contrast enhancement in cranial and spinal MRI, magnetic resonance angiography, and whole-body imaging, encompassing the liver and kidneys.
This advanced imaging agent is especially beneficial for patients with high suspicion or evidence of focal lesions, as it can accurately classify them as benign or malignant. Gadobutrol, the key component of Pixxoscan, boasts a high relaxivity that enhances detection, delineation, and characterisation in MRI across its wide array of indications. Furthermore, it is formulated at double the concentration of gadolinium ions, allowing for a 50% reduction in injection volume compared to other gadolinium-based contrast agents (GBCAs). This results in a tighter bolus, optimising the imaging process.
Another noteworthy aspect of Pixxoscan is its cage-like macrocyclic chelate structure surrounding the gadolinium. This unique structure offers high kinetic stability, ensuring the contrast agent remains intact and safe throughout its use. As part of GE Healthcare’s MRI contrast media portfolio, Pixxoscan joins other macrocyclic agents like Clariscan (gadoteric acid) and Rapiscan, employed in stress cardiac MR to diagnose coronary artery disease and provide an alternative for patients who cannot exercise.
Introducing Pixxoscan to the market will grant radiology departments increased access to contrast agents that support a diverse range of MRI procedures. This, in turn, will enable healthcare professionals to personalise care for their patients, tailoring their approach to suit each individual’s unique needs and conditions. Furthermore, by offering enhanced detection and visualisation capabilities, Pixxoscan is poised to revolutionise the field of diagnostic imaging, improving patient outcomes and streamlining the diagnostic process for medical professionals worldwide.
MRI Agent Pixxoscan: Indications and Applications
Gadobutrol is employed across various diagnostic imaging applications, including cranial and spinal MRI, MRA, and whole-body imaging. It is beneficial in detecting and characterising focal lesions in organs such as the liver and kidneys, allowing for the accurate classification of benign or malignant tumours. The enhanced imaging capabilities of gadobutrol enable clinicians to make more accurate diagnoses and devise targeted treatment plans for patients.
In addition to its applications in neuroimaging and oncology, gadobutrol is also used in cardiovascular imaging, such as stress cardiac MR, to aid in diagnosing coronary artery disease. In addition, it provides an alternative imaging option for patients unable to exercise or undergo traditional stress testing.
Conclusion
Gadobutrol has established itself as a vital component of the diagnostic imaging toolkit. It offers radiology departments enhanced visualisation of abnormal structures or lesions, aiding in the differentiation between healthy and pathological tissue. In addition, its high relaxivity, and unique cage-like macrocyclic chelate structure provide a stable, effective, and relatively safe option for contrast enhancement in MRI and MRA procedures. However, as research into the long-term effects of gadolinium-based contrast agents continues, the medical community must remain vigilant to optimise patient care while minimising potential risks.
As diagnostic imaging continues to evolve, gadobutrol will likely play a significant role in shaping its future. Its wide range of applications and favourable safety profile is a testament to the potential of contrast-enhanced imaging in improving patient outcomes and advancing our understanding of complex medical conditions. By staying informed about the latest developments in contrast agent research and technology, healthcare professionals can continue to harness the power of gadobutrol and other imaging agents to provide personalised, high-quality care to their patients.
You are here: home »